Multiple myeloma
Cytokine stimulation can increase the potency and durability of engineered TÂ cells
TurboCARâ„¢ is designed to recapitulate cytokine signaling selectively in CAR T cells and may have potential benefits, subject to investigation
- Minimizes systemic toxicity
- Does not stimulate host immune cells which could reject CAR
- Delivers survival benefit selectively to CAR T cells
Opportunities for development
- Improving the efficacy of CAR T cells
- Reducing CAR T cell dose requirement
- Overcoming exhaustion to enable CAR T therapies to be used for solid tumors